Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
| Condition | Pancreatic Cancer |
|---|---|
| Phase | Phase 2 |
| Sponsor | Massachusetts General Hospital |
| Status | Completed |
| Enrollment | 50 participants |
| Interventions | Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy |
| Start date | Dec 27, 2011 |
| Completion date | Sep 16, 2018 |
| Results posted | Aug 5, 2026 |
Summary
A standard treatment for patients with pancreatic cancer is standard photon radiation in combination with the chemotherapy drug, capecitabine. In this research study the investigators are using standard photon radiation or a different type of radiation therapy called proton beam radiation and adding hydroxychloroquine to be used in combination with capecitabine. In this research study, the investigators are looking to determine if proton or photon beam radiation in combination with hydroxychloroquine and capecitabine is effective in controlling your cancer growth.
Progression-free Survival
| Hydroxychloroquine | 16 Participants |
|---|---|
| Hydroxychloroquine | 10 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group
- A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) — University of Iowa